Publications

August 2001 (Revised April 2003)
Case

International Trachoma Initiative

By: Diana Barrett, James E. Austin and Sheila McCarthy

In an effort to combat trachoma, a major eye disease, the Clark Foundation entered into a partnership with Pfizer Pharmaceuticals. After a successful pilot project, a joint initiative was established (the Trachoma initiative) that has as its goal to eradicate the... View Details

Keywords: For-Profit Firms; Joint Ventures; Globalization; Mission and Purpose; Organizational Culture; Alliances; Partners and Partnerships; Non-Governmental Organizations; Health Industry

11 May 2011
News

A New Era of Entrepreneurship

2020
Working Paper

What Can Economics Say About Alzheimer's Disease?

By: Amitabh Chandra, Courtney Coile and Corina Mommaerts

Alzheimer’s Disease (AD) affects one in ten people aged 65 or older and is the most expensive disease in the United States. We describe the central economic questions raised by AD. While there is overlap with the economics of aging, the defining features of the... View Details

Keywords: Health Disorders; Health Care and Treatment; Economics

February 2000
Case

E2M Health Services

By: Richard M.J. Bohmer and Naomi Atkins

Outlines the growth of an innovative diabetes disease management organization from 1994-99. Having demonstrated the success of their model in managing diabetes populations in Texas and New York State, the CEO and president must decide the future strategy of the company... View Details

Keywords: Business Model; Customer Focus and Relationships; Decision Choices and Conditions; Financial Markets; Revenue; Innovation and Invention; Business or Company Management; Marketing Strategy; Internet; Health Industry

29 Apr 2020
News

What Makes an Office Building “Healthy”

29 Oct 2015
News

Walgreens-Rite Aid merger would pose challenge to CVS

September 2023
Case

Healthy.io: The Negotiation for the Medical Selfie

By: Amit Goldenberg and Kumba Sennaar

Healthy.io, an Israeli digital health company, prepares to enter the U.S. market with its chronic kidney disease test. A product safety approval is delayed, putting the company’s cash runway at risk. How should the CEO negotiate his offer to insurance companies ahead... View Details

Keywords: Negotiation; Entrepreneurship; Venture Capital; Operations; Business Startups; Market Entry and Exit; Health Industry; Israel; United Kingdom; United States

February 2024 (Revised December 2024)
Case

Best Buy Health: Enabling Care at Home

By: Robert S. Huckman, Rosabeth Moss Kanter, Antonio Moreno, Bradley Staats and Sarah Mehta

This case explores retailer Best Buy’s decision to enter health care. Best Buy Health aims to enable care at home across three prongs: consumer health, active aging, and virtual care. A key pillar of Best Buy Health's strategy is leveraging the Geek Squad—the company's... View Details

Keywords: Business Ventures; Health Care and Treatment; Innovation and Invention; Business Strategy; Market Entry and Exit; Service Delivery; Service Operations; Electronics Industry; Health Industry; Retail Industry; United States; Minnesota

October 2014 (Revised September 2017)
Case

The National Football League and Brain Injuries

By: Richard G. Hamermesh and Matthew G. Preble

The National Football League (NFL) was both the most popular spectator sport in the U.S. and a major economic entity, taking in roughly $10 billion a year in revenue. However through the early twenty-first century, an increased understanding of the long-term effects of... View Details

Keywords: Employee Safety; Safety; Employees; Sports; Health; Ethics; Sports Industry; United States

Article

The Unprecedented Stock Market Reaction to COVID-19

By: Scott Baker, Nicholas Bloom, Steven J. Davis, Kyle Kost, Marco Sammon and Tasaneeya Viratyosin

No previous infectious disease outbreak, including the Spanish Flu, has impacted the stock market as forcefully as the COVID-19 pandemic. In fact, previous pandemics left only mild traces on the U.S. stock market. We use text-based methods to develop these points with... View Details

Keywords: COVID-19; Stock Market; Health Pandemics; Governance; Policy; Financial Markets

June 2004 (Revised November 2004)
Case

Acorda Therapeutics: Rebuilding the Spinal Cord

Acorda is an early-stage life science start-up with a promising product that is close to reaching the market (Phase III clinical trials). The company is grappling with how to expand its portfolio of molecules to make the business more sustainable. It faces classic... View Details

Keywords: Decision Making; Science-Based Business; Health Testing and Trials; Business Startups; Product Development; Biotechnology Industry

14 Nov 2019
Video

Health Minute: How Can Companies Bring "Missing Drugs" to Market?

2020
Working Paper

Aggregate and Firm-Level Stock Returns During Pandemics, in Real Time

By: Laura Alfaro, Anusha Chari, Andrew Greenland and Peter K. Schott

We show that unexpected changes in the trajectory of COVID-19 infections predict U.S. stock returns, in real time. Parameter estimates indicate that an unanticipated doubling (halving) of projected infections forecasts next-day decreases (increases) in aggregate U.S.... View Details

Keywords: COVID-19; Stock Returns; Health Pandemics; Stocks; Investment Return; Forecasting and Prediction

2024
Working Paper

HIV Tests and AIDS Treatments—Containing a Fearsome Pandemic: Case Histories of Transformational Advances

By: Amar Bhidé, Srikant M. Datar and Katherine Stebbins

This case history describes how a diverse cast of characters, including public health organizations, research laboratories, for-profit healthcare companies, activists, and regulators, rolled back the outbreak of HIV/AIDS in just fifteen years. Moreover, as the case... View Details

Keywords: Health Care and Treatment; Technological Innovation; Innovation Strategy; Technology Adoption; Collaborative Innovation and Invention; Innovation and Invention; Governing Rules, Regulations, and Reforms

SSRN

November 2001 (Revised September 2004)
Case

Evolution of Treatment, The: The Case of Diabetes

By: Richard M.J. Bohmer, Jeffrey D. Street and Laura Feldman

Scientific knowledge surrounding diabetes mellitus has grown over the last century to include its cause, treatment, and prevention strategies. However, the type and level of care that patients receive is suboptional. This case examines the forces in industry,... View Details

Keywords: Policy; Health Care and Treatment; Innovation and Management; Knowledge Use and Leverage; Management; Management Analysis, Tools, and Techniques; Health Industry

Jason Pananos is a Senior Lecturer of Business Administration in the Finance Department. Jason currently teaches and was the co-creator of a second-year field course titled “Value Creation in Small and Medium Firms”. Jason is also an active collaborator and guest... View Details

October 2019
Article

Adaptive Platform Trials: Definition, Design, Conduct and Reporting Considerations

By: Derek C. Angus, Brian M. Alexander, Scott Berry, Meredith Buxton, Roger Lewis, Melissa Paoloni, Steven A. R. Webb, Steven Arnold, Anna Barker, Donald A. Berry, Marc J. M. Bonten, Mary Brophy, Christopher Butler, Timothy F. Cloughesy, Lennie P. G. Derde, Laura J. Esserman, Ryan Ferguson, Louis Fiore, Sarah C. Gaffey, J. Michael Gaziano, Kathy Giusti, Herman Goossens, Stephane Heritier, Bradley Hyman, Michael Krams, Kay Larholt, Lisa M. LaVange, Philip Lavori, Andrew W. Lo, Alexander J. London, Victoria Manax, Colin McArthur, Genevieve O’Neill, Giovanni Parmigiani, Jane Perlmutter, Elizabeth A. Petzold, Craig Ritchie, Kathryn M. Rowan, Christopher W. Seymour, Nathan I. Shapiro, Diane M. Simeone, Bradley Smith, Bradley Spellberg, Ariel Dora Stern, Lorenzo Trippa, Mark Trusheim, Kert Viele, Patrick Y. Wen and Janet Woodcock

Researchers, clinicians, policymakers, and patients are increasingly interested in questions about therapeutic interventions that are difficult or costly to answer with traditional, free-standing, parallel-group randomized controlled trials (RCTs). Examples include... View Details

Keywords: Adaptive Platform Trials; Health Testing and Trials

August 2009 (Revised April 2012)
Case

Genzyme's CSR Dilemma: How to Play its HAND

By: Christopher A. Bartlett, Tarun Khanna and Prithwiraj Choudhury

Genzyme, a global biotechnology company, launches a program to develop therapies for neglected diseases (e.g., malaria, TB), giving away the intellectual property. This case focuses on the decision of which diseases, which partnerships, and which markets should... View Details

Keywords: Global Strategy; Health Care and Treatment; Intellectual Property; Corporate Social Responsibility and Impact; Partners and Partnerships; Research and Development; Biotechnology Industry